Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Update on Asthma-COPD Overlap (ACO): A Narrative Review

    Publikation: Bidrag til tidsskriftReviewpeer review

  4. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

BACKGROUND: Systemic corticosteroid administration for severe acute exacerbations of COPD (AECOPD) reduces the duration of hospital stays. Corticosteroid-sparing regimens have showed non-inferiority to higher accumulated dose regimens regarding re-exacerbation risk in patients with AECOPD. However, it remains unclear whether 14-day or 2-5-day regimens would result in shorter admission durations and changes in mortality risk. We explored this by analysing the number of days alive and out of hospital based on two randomised controlled trials with different corticosteroid regimens.

METHODS: We pooled individual patient data from the two available multicentre randomised trials on corticosteroid-sparing regimens for AECOPD: the REDUCE (n = 314) and CORTICO-COP (n = 318) trials. In the 14-day regimen group, patients were older, fewer patients received pre-treatment with antibiotics and more patients received pre-treatment with systemic corticosteroids. Patients randomly allocated to the 14-day and 2-5-day regimens were compared, with adjustment for baseline differences.

RESULTS: The number of days alive and out of hospital within 14 days from recruitment was higher for the 2-5 day regimen group (mean 8.4 days; 95% confidence interval [CI] 8.0-8.8) than the 14-day regimen patient group (4.2 days; 95% CI3.4-4.9; p < 0.001). The 14-day AECOPD group had longer hospital stays (mean difference, 5.4 days [standard error ± 0.6]; p < 0.0001) and decreased likelihood of discharge within 30 days (hazard ratio [HR] 0.5; 95% CI 0.4-0.6; p < 0.0001). Comparing the 14-day regimen and the 2-5 day regimen group showed no differences in the composite endpoint 'death or ICU admission' (odds ratio [OR] 1.4; 95% CI 0.8-2.3; p = 0.15), new or aggravated hypertension (OR 1.5; 95% CI 0.9-2.7; p = 0.15), or mortality risk (HR 0.8; 95% CI 0.4-1.5; p = 0.45) during the 6-month follow-up period.

CONCLUSION: 14-day corticosteroid regimens were associated with longer hospital stays and fewer days alive and out of hospital within 14 days, with no apparent 6-month benefit regarding death or admission to ICU in COPD patients. Our results favour 2-5 day regimens for treating COPD exacerbations. However, prospective studies are needed to validate these findings.

TidsskriftRespiratory Research
Udgave nummer1
Sider (fra-til)155
StatusUdgivet - 21 maj 2021

Bibliografisk note

Funding Information:
This study was funded by the Danish Regions Medical Fund (Grant No. 5894/16) and the Danish Council for Independent Research (Grant No. 6110-00268B). The research salary for P.S. was provided by Herlev-Gentofte University Hospital. Alexander G. Mathioudakis and Jørgen Vestbo were supported by the National Institute for Health Research (NIHR) and Manchester Biomedical Research Centre (BRC).

Funding Information:
REDUCE: We thank project nurses Ursula Duerring, Yolanda Leibbrandt, and Sabrina Maier for their work on this project. CORTICO-COP: We are grateful for the work performed by project nurse Svenja Andersen and medical student Freja St?hr Holm. We would like to thank all the relevant departments in the Capital Region of Denmark and the participating hospitals in Switzerland for allowing us to recruit patients. We would also like to thank the COP:TRIN Steering Committee for their helpful advice.

ID: 65795554